Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 1
2016 1
2023 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
The following term was not found in PubMed: Bhaaskaran
Page 1
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators. Salloway S, et al. N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839. N Engl J Med. 2014. PMID: 24450891 Free PMC article. Clinical Trial.
BACKGROUND: Bapineuzumab, a humanized anti-amyloid-beta monoclonal antibody, is in clinical development for the treatment of Alzheimer's disease. METHODS: We conducted two double-blind, randomized, placebo-controlled, phase 3 trials involving patients with mild-to-moderate …
BACKGROUND: Bapineuzumab, a humanized anti-amyloid-beta monoclonal antibody, is in clinical development for the treatment of Alzheimer's …
Safety and efficacy of continuous subcutaneous levodopa-carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial.
Espay AJ, Stocchi F, Pahwa R, Albanese A, Ellenbogen A, Ferreira JJ, Giladi N, Gurevich T, Hassin-Baer S, Hernandez-Vara J, Isaacson SH, Kieburtz K, LeWitt PA, Lopez-Manzanares L, Olanow CW, Poewe W, Sarva H, Yardeni T, Adar L, Salin L, Lopes N, Sasson N, Case R, Rascol O; BouNDless Study Group. Espay AJ, et al. Lancet Neurol. 2024 May;23(5):465-476. doi: 10.1016/S1474-4422(24)00052-8. Epub 2024 Mar 15. Lancet Neurol. 2024. PMID: 38499015 Clinical Trial.
BACKGROUND: Conventional oral levodopa therapy for the treatment of Parkinson's disease can be associated with variations in plasma concentrations. ...Eligible participants were men and women aged 30 years or older with a diagnosis of Parkinson's disease (Hoehn and …
BACKGROUND: Conventional oral levodopa therapy for the treatment of Parkinson's disease can be associated with variations in plasma c …
Piper betle extract and its application in bovine teat dipping solution inhibit and eliminate biofilms in bovine mastitis-inducing staphylococci.
Sungkatavat P, Khongkhai H, Kanchana W, Saengsawarng P, Sangkanu S, Nissapatorn V, Pereira ML, Ontong JC, Mitsuwan W. Sungkatavat P, et al. Vet World. 2023 Oct;16(10):2135-2142. doi: 10.14202/vetworld.2023.2135-2142. Epub 2023 Oct 18. Vet World. 2023. PMID: 38023268 Free PMC article.
RESULTS: The extract exhibited potent antibacterial activity against S. aureus and S. haemolyticus, with similar values for minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) ranging from 0.03 mg/mL to 0.125 mg/mL. The MIC and MBC va …
RESULTS: The extract exhibited potent antibacterial activity against S. aureus and S. haemolyticus, with similar values for mi …
Coexistence of electron and phonon topology in conjunction with quantum transport device modeling.
V AC, Pradhan SS, Kanchana V. V AC, et al. J Phys Condens Matter. 2024 Jan 19;36(15). doi: 10.1088/1361-648X/ad1a5b. J Phys Condens Matter. 2024. PMID: 38171025
Furthermore, the monolayer has been proposed as a two-terminal device model to investigate the quantum transport properties using the non-equilibrium Green's function approach. This superlative combination of observations and modeling sets the path for a greater level of i …
Furthermore, the monolayer has been proposed as a two-terminal device model to investigate the quantum transport properties using the non-eq …
Fermi surface properties of AB3 (A = Y, La; B = Pb, In, Tl) intermetallic compounds under pressure.
Ram S, Kanchana V, Svane A, Dugdale SB, Christensen NE. Ram S, et al. J Phys Condens Matter. 2013 Apr 17;25(15):155501. doi: 10.1088/0953-8984/25/15/155501. Epub 2013 Mar 25. J Phys Condens Matter. 2013. PMID: 23528988
Fermi surface topology changes are found for all the isostructural AB3 compounds under compression (at V/V0 = 0.90 for LaPb3 (pressure = 8 GPa), at V/V0 = 0.98 for AIn3 (pressure = 1.5 GPa), at V/V0 = 0.80 for ATl3 (pressure in excess of 18 GPa)) apart from Y …
Fermi surface topology changes are found for all the isostructural AB3 compounds under compression (at V/V0 = 0.90 for LaPb3 (pressur …
Predicted superconductivity of Ni2VAl and pressure dependence of superconductivity in Ni2NbX (X  =  Al, Ga and Sn) and Ni2VAl.
Sreenivasa Reddy PV, Kanchana V, Vaitheeswaran G, Singh DJ. Sreenivasa Reddy PV, et al. J Phys Condens Matter. 2016 Mar 23;28(11):115703. doi: 10.1088/0953-8984/28/11/115703. Epub 2016 Feb 23. J Phys Condens Matter. 2016. PMID: 26902514 Free article.
The electronic density of states reveals a significant hybridization between Ni-eg and V-t(2g) states around the Fermi level. The Fermi surface, consisting of two electron pockets around the X-points of the Brillouin zone, exhibits nesting and leads to a Kohn anomaly of th …
The electronic density of states reveals a significant hybridization between Ni-eg and V-t(2g) states around the Fermi level. The Fer …